Tenon Medical (TNON) has received U.S. Food and Drug Administration 510(k) clearance for the SImmetry+ SI Joint Fusion System. The SImmetry+ System is indicated for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis, providing physicians with treatment options rooted in established fusion principles.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNON: